https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43672 Wed 28 Sep 2022 14:35:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31068 Wed 24 Nov 2021 15:51:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47060 Wed 13 Mar 2024 08:04:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25152 Wed 11 Apr 2018 13:49:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20997 n = 144) in a multicultural high school in Western Sydney completed the asthma symptoms ISAAC video questionnaire (AVQ3.0), spirometry and allergy skin prick tests. A dietitian administered a 'Food Frequency' and 'Food Habits' questionnaire and a dietary history interview. Results: Students who spoke a language other than English, consumed a traditional or mixed dietary pattern, with lower consumption of saturated fat, compared to students who spoke English only. Saturated fat intake increased and fibre intake decreased with length of time in Australia. Intake of foods high in saturated or trans fatty acids were positively associated with length of stay in Australia. No associations between nutrient intake or whole food intake and self-reported wheeze were observed. Conclusion: As time progressed, dietary intake of immigrant children changed. While this was not associated with the development of wheeze in the students in this cohort, these changes are likely to have negative health consequences.]]> Wed 11 Apr 2018 11:16:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32913 Wed 09 Mar 2022 16:01:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43636 Tue 27 Sep 2022 09:39:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54436 Tue 27 Feb 2024 13:49:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39820 Tue 26 Jul 2022 11:33:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45086 25 billion CFU) and placebo. Plasma SCFA, sputum cell counts and inflammatory gene expression, asthma control gut microbiota, adverse events including gastrointestinal symptoms were measured. Findings: There was no difference in change in total plasma SCFA levels (μmol/L) in the placebo versus soluble fibre (Δmedian [95% CI] 16·3 [−16·9, 49·5], p = 0·335) or soluble fibre+probiotic (18·7 [−14·5, 51·9], p = 0·325) group. Following the soluble fibre intervention there was an improvement in the asthma control questionnaire (ACQ6) (∆median (IQR) -0·35 (−0·5, −0·13), p = 0·006), sputum %eosinophils decreased (−1.0 (−2·5, 0), p = 0·006) and sputum histone deacetylase 9 (HDAC9) gene expression decreased (−0.49 (−0.83, −0.27) 2^-ΔCt, p = .008). Individual bacterial operational taxonomic units changed following both inulin and inulin+probiotic arms. Interpretation: Soluble fibre supplementation for 7 days in adults with asthma did not change SCFA levels. Within group analysis showed improvements in airway inflammation, asthma control and gut microbiome composition following inulin supplementation and these changes warrant further investigation, in order to evaluate the potential of soluble fibre as a non-pharmacological addition to asthma management.]]> Thu 27 Oct 2022 14:06:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34928 Thu 22 Aug 2024 10:37:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50862 Thu 17 Aug 2023 11:36:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19687 Sat 24 Mar 2018 07:53:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19996 Sat 24 Mar 2018 07:50:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48193 Sat 11 Mar 2023 12:30:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48173 Sat 11 Mar 2023 12:23:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39780 Mon 25 Jul 2022 11:26:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44812 Mon 24 Oct 2022 09:38:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55458 Mon 03 Jun 2024 08:51:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48926 Mon 01 May 2023 08:56:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33965 Fri 25 Jan 2019 14:42:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34249 Fri 22 Feb 2019 16:55:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37059 Fri 21 Aug 2020 11:53:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46107 −2) versus healthy-weight (BMI <25 kg·m⁻²) subjects with asthma. Design Databases including CINAHL (Cumulative Index to Nursing and Allied Health Literature), Cochrane, Embase and MEDLINE were searched up to July 2019 for English-language studies that recorded medication use or dose in obese and healthy-weight adults with asthma. A critical appraisal checklist was utilised for scrutinising methodological quality of eligible studies. Meta-analysis was performed and heterogeneity was examined with the use of the Chi-squared test. This review was conducted based on a published protocol (www.crd.york.ac.uk/PROSPERO CRD42020148671). Results Meta-analysis showed that obese subjects are more likely to use asthma medications, including short-acting β2-agonists (OR 1.75, 95% CI 1.17–2.60; p=0.006, I²=41%) and maintenance oral corticosteroids (OR 1.86, 95% CI 1.49–2.31; p<0.001, I2=0%) compared to healthy-weight subjects. Inhaled corticosteroid (ICS) dose (µg·day⁻¹) was significantly higher in obese subjects (mean difference 208.14, 95% CI 107.01–309.27; p<0.001, I²=74%). Forced expiratory volume in 1 s (FEV₁) % predicted was significantly lower in obese subjects (mean difference −5.32%, 95% CI −6.75–−3.89; p<0.001, I²=42%); however, no significant differences were observed in FEV₁/forced vital capacity (FVC) ratio between groups. Conclusions We found that obese subjects with asthma have higher use of all included asthma medication classes and higher ICS doses than healthy-weight asthma subjects, despite lower FEV₁ and a similar FEV₁/FVC %. A better understanding of the factors driving increased medication use is required to improve outcomes in this subgroup of asthmatics.]]> Fri 11 Nov 2022 15:35:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30780 Fri 03 Dec 2021 10:34:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32830 Fri 03 Dec 2021 10:34:06 AEDT ]]>